Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022

Supplemental Figure 1: Variation in EGFR and PDL1 testing in the Mid-south Quality of Surgical Resection cohort by Patient-, Provider-, and Institutional-level factors spanning a four year period including the first two years of FDA approval of Osimertinib for adjuvant therapy in non-small cell lung cancer 2018 to 2022. Significant results at the 0.05 level are denoted (*) for EGFR and (^) for PDL1. CoC, Commission on Cancer; ACCP, Academic Comprehensive Cancer Program; CCP, Comprehensive Community Cancer Program.